Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$976K Hold
3,877
0.9% 25
2026
Q1
$843K Sell
3,877
-490
-11% -$109K 0.79% 21
2025
Q4
$998K Hold
4,367
0.94% 20
2025
Q3
$1.01M Hold
4,367
0.76% 28
2025
Q2
$811K Hold
4,367
0.48% 50
2025
Q1
$915K Buy
+4,367
New +$849K 0.65% 23

Other funds holding ABBV

Corient IA's ABBV Position: Q2 2026 in Review

Corient IA held its AbbVie (ABBV) position steady in Q2 2026 at 3,877 shares worth $976K. The position accounts for 0.9% of the portfolio, ranked #25.

Corient IA first reported a position in ABBV in Q1 2025 and has held it in 6 quarters since. The position peaked at $1.01M in Q3 2025. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Corient IA held 3,877 shares of AbbVie worth $976K as of Q2 2026.
  • Corient IA left its AbbVie share count unchanged in Q2 2026.
  • AbbVie made up 0.9% of Corient IA's portfolio in Q2 2026, its #25 holding.
  • Corient IA first reported a position in AbbVie in Q1 2025 and has held it in 6 quarters since.
  • Corient IA's AbbVie position peaked at $1.01M in Q3 2025.
  • 4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Corient IA's 13F filing for Q2 2026, filed 12 Aug 2026.